Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120).
Zukin M, Gondim V, Shimada AK, Lima EMEA, Mathias C, Barra WF, William Junior WN, Padoan M, Bittencourt Y, Yamamura R, Silva CEB, Rossato LJ, Monteiro CA, Jesus RG, Gössling G, Gelatti ACZ. Zukin M, et al. Among authors: padoan m. J Bras Pneumol. 2025 Jan 13;50(6):e20240228. doi: 10.36416/1806-3756/e20240228. eCollection 2025. J Bras Pneumol. 2025. PMID: 39813498
Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC-RELANCE/LACOG 0118.
Cordeiro de Lima VC, Gelatti A, Moura JFP, Fares AF, de Castro G Jr, Mathias C, Terra RM, Werutsky G, Corassa M, Araújo LHL, Cronenberger E, Fujiki FK, Reichow S, da Silva AVT, Reis TV, Padoan MLA, Pacheco P, Yamamura R, Kawamura C, Mascarenhas E, de Jesus RG, Gössling G, Baldotto C. Cordeiro de Lima VC, et al. Among authors: padoan mla. JTO Clin Res Rep. 2024 Feb 3;5(3):100646. doi: 10.1016/j.jtocrr.2024.100646. eCollection 2024 Mar. JTO Clin Res Rep. 2024. PMID: 38434771 Free PMC article.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Free PMC article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial.
Ominelli J, Araujo ROC, Valadão M, Padoan MLA, Lopes Dos Santos VM, Dutra JG, Torres CC, Barbosa MA, Guimarães R, Carvalho JCC, Ferreira MA, de Oliveira IM, Small I, de Melo AC, Araujo LH. Ominelli J, et al. Among authors: padoan mla. Clin Colorectal Cancer. 2022 Sep;21(3):e196-e204. doi: 10.1016/j.clcc.2022.05.002. Epub 2022 May 13. Clin Colorectal Cancer. 2022. PMID: 35668002 Clinical Trial.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Night shift work and lymphoma: results from an Italian multicentre case-control study.
Cocco P, Piro S, Meloni F, Montagna A, Pani M, Pilia I, Padoan M, Miligi L, Magnani C, Gambelunghe A, Muzi G, Ferri GM, Vimercati L, Zanotti R, Scarpa A, Zucca M, Latte GC, Angelucci E, De Matteis S, Puligheddu M. Cocco P, et al. Among authors: padoan m. Occup Environ Med. 2022 Jul;79(7):452-459. doi: 10.1136/oemed-2021-107845. Epub 2022 Jan 13. Occup Environ Med. 2022. PMID: 35027441
Occupational exposure to glyphosate and risk of lymphoma:results of an Italian multicenter case-control study.
Meloni F, Satta G, Padoan M, Montagna A, Pilia I, Argiolas A, Piro S, Magnani C, Gambelunghe A, Muzi G, Ferri GM, Vimercati L, Zanotti R, Scarpa A, Zucca M, De Matteis S, Campagna M, Miligi L, Cocco P. Meloni F, et al. Among authors: padoan m. Environ Health. 2021 Apr 28;20(1):49. doi: 10.1186/s12940-021-00729-8. Environ Health. 2021. PMID: 33910586 Free PMC article.
Genetically Determined Height and Risk of Non-hodgkin Lymphoma.
Moore A, Kane E, Wang Z, Panagiotou OA, Teras LR, Monnereau A, Wong Doo N, Machiela MJ, Skibola CF, Slager SL, Salles G, Camp NJ, Bracci PM, Nieters A, Vermeulen RCH, Vijai J, Smedby KE, Zhang Y, Vajdic CM, Cozen W, Spinelli JJ, Hjalgrim H, Giles GG, Link BK, Clavel J, Arslan AA, Purdue MP, Tinker LF, Albanes D, Ferri GM, Habermann TM, Adami HO, Becker N, Benavente Y, Bisanzi S, Boffetta P, Brennan P, Brooks-Wilson AR, Canzian F, Conde L, Cox DG, Curtin K, Foretova L, Gapstur SM, Ghesquières H, Glenn M, Glimelius B, Jackson RD, Lan Q, Liebow M, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Morton LM, North KE, Offit K, Padoan M, Patel AV, Piro S, Ravichandran V, Riboli E, de Sanjose S, Severson RK, Southey MC, Staines A, Stewart C, Travis RC, Weiderpass E, Weinstein S, Zheng T, Chanock SJ, Chatterjee N, Rothman N, Birmann BM, Cerhan JR, Berndt SI. Moore A, et al. Among authors: padoan m. Front Oncol. 2020 Jan 28;9:1539. doi: 10.3389/fonc.2019.01539. eCollection 2019. Front Oncol. 2020. PMID: 32064237 Free PMC article.
Methylation alteration of SHANK1 as a predictive, diagnostic and prognostic biomarker for chronic lymphocytic leukemia.
Loi E, Moi L, Fadda A, Satta G, Zucca M, Sanna S, Amini Nia S, Cabras G, Padoan M, Magnani C, Miligi L, Piro S, Gentilini D, Ennas MG, Southey MC, Giles GG, Wong Doo N, Cocco P, Zavattari P. Loi E, et al. Among authors: padoan m. Oncotarget. 2019 Aug 13;10(48):4987-5002. doi: 10.18632/oncotarget.27080. eCollection 2019 Aug 13. Oncotarget. 2019. PMID: 31452839 Free PMC article.
27 results